Dr. Jon D. Oden, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- Medical school
- Texas Tech University Health Science Center School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Texas Tech University Health Science Center School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
AR license E-9163 · TX license K5644 (first issued 1998; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arkansas Childrens Professional Services Organization LLC (184 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Little Rock, AR | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $22,913 in total to this clinician.
| Sanofi-aventis U.S. LLC | $12,386 |
|---|---|
| Genzyme Corporation | $10,272 |
| Abbott Laboratories | $220 |
| Soleno Therapeutics, Inc. | $19.14 |
| Eton Pharmaceuticals, Inc. | $15.75 |
| Consulting Fee | $20,610 |
|---|---|
| Travel and Lodging | $1,195 |
| Food and Beverage | $888 |
| Long term medical supply or device loan | $220 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Jul 17, 2025 | Consulting Fee | $10,992 |
| Genzyme Corporation Oct 3, 2025 | Consulting Fee | $9,618 |
| Sanofi-aventis U.S. LLC Jul 16, 2025 | Travel and Lodging travel to Detroit, MI · in-kind | $603 |
| Genzyme Corporation Oct 4, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $305 |
| Sanofi-aventis U.S. LLC Jul 17, 2025 | Travel and Lodging travel to Detroit, MI · in-kind | $288 |
| Abbott Laboratories Apr 23, 2025 | Long term medical supply or device loan FREESTYLE COPILOT · Diabetes Care · in-kind | $110 |
| Abbott Laboratories Apr 23, 2025 | Long term medical supply or device loan FREESTYLE COPILOT · Diabetes Care · in-kind | $110 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $12,350 in research payments for these studies, mostly to the institutions running them.
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company · Recruiting · NCT06739122 - A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL)
Sanofi US Services Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.